1/16/2019 7:03:44 AM
Acceleron Pharma Prices Public Offering Of 5.35 Mln Shares At $43/Shr For Gross Proceeds Of $230.0 Mln
1/14/2019 4:06:45 PM
Acceleron Announces Proposed Public Offering Of Common Stock
12/2/2018 5:40:17 PM
Celgene And Acceleron Pharma Announce Results Of Phase 3 MEDALIST Trial Evaluating Luspatercept In Patients With MDS
11/28/2018 7:10:00 AM
Acceleron Receives FDA Fast Track Designation For ACE-083 In Charcot-Marie-Tooth Disease
7/23/2018 7:03:55 AM
Acceleron Announces Positive Preliminary Results From Part 1 Of The ACE-083 Phase 2 Trial
7/12/2018 7:04:39 AM
Acceleron Pharma Says FDA Granted Orphan Drug Designation For ACE-083
7/5/2018 4:31:51 PM
Acceleron Appoints Robert Zeldin As Chief Medical Officer
6/26/2018 7:06:45 AM
Acceleron To Present Preliminary Data On ACE-083 At 2018 Annual Meeting Of The Peripheral Nerve Society
6/15/2018 7:00:23 AM
Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Beta-Thalassemia
6/4/2018 7:07:26 AM
Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes
5/24/2018 10:36:58 AM
Prevail Therapeutics Appoints Francois Nader To Its Board
5/22/2018 7:00:22 AM
Acceleron Begins PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension